Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25851225 | 0.90 | — | — | |
| SCHEMBL25835897 | 0.77 | CA14 (0.41) | L3MBTL1BLMPMP22HSD17B10HDAC1 | |
| SCHEMBL24340623 | 0.76 | CA14 (0.40) | L3MBTL1BLMPMP22HSD17B10HDAC1 | |
| SCHEMBL18281954 | 0.75 | CTSS (0.34) | L3MBTL1HDAC1HDAC2HDAC6 | |
| SCHEMBL26689402 | 0.75 | BLM (0.38) | L3MBTL1BLMPMP22HSD17B10HDAC1 | |
| SCHEMBL946261 | 0.75 | BLM (0.38) | L3MBTL1BLMPMP22HSD17B10HDAC1 | |
| SCHEMBL18285697 | 0.74 | CA14 (0.37) | L3MBTL1HDAC1HDAC2HDAC6 | |
| SCHEMBL23564375 | 0.74 | CTSL (0.37) | HDAC1HDAC2HDAC6 | |
| SCHEMBL13567944 | 0.73 | CA14 (0.34) | L3MBTL1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL30104830 | 0.72 | HDAC6 (0.32) | HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | L3MBTL1 569/4885CHRNB2 251/4885CHRNA4 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.